Edgar Filing: Schenkein David P - Form 4

Schenkein I Form 4	David P										
June 01, 201	18										
FORM	14		GEGU						OMB AF	PROVAL	
	STTIES A shington,			NGE CO	OMMISSION	OMB Number:	3235-0287				
Check this box if no longer subject to Section 16. Form 4 or					DENEE				Expires:	January 31, 2005	
				SECUR	RITIES				Estimated a burden hour response	verage	
Form 5 obligations may continue.Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 19401(b).30(h) of the Investment Company Act of 1940											
(Print or Type	Responses)										
Schenkein David P Symbol								5. Relationship of Reporting Person(s) to Issuer			
			AGIOS PHARMACEUTICALS INC [AGIO]					(Check all applicable)			
(Last)						_X_ Director _X_ Officer (give t	title Othe	Owner r (specify			
C/O AGIO PHARMAC SIDNEY S	CEUTICALS, IN	C., 88	05/30/2	-			1	below) Chief E	below) xecutive Office	er	
				endment, Date Original				6. Individual or Joint/Group Filing(Check			
Filed(Mo CAMBRIDGE, MA 02139				onth/Day/Year)				Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting Person			
(City)	(State)	(Zip)	Tab	le I - Non-I	Derivative	Secur	ities Acqu	ired, Disposed of,	or Beneficiall	y Owned	
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)		Date, if	3. Transactio Code (Instr. 8)		ed of (and f (A)	(D)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code V	Amount	or (D)	Price	(Instr. 3 and 4)			
Common stock	05/30/2018			M <u>(1)</u>	5,962	А	\$ 0.3025	5,962	D		
Common stock	05/30/2018			M <u>(1)</u>	16,193	А	\$ 0.3025	22,155	D		
Common stock	05/30/2018			M <u>(1)</u>	23,471	A	\$ 0.4675	45,626	D		
Common stock	05/30/2018			S <u>(2)</u>	45,626	D	\$ 90.07 (3)	0	D		
								271,772	Ι		

Edgar Filing: Schenkein David P - Form 4

Common stock Common							79,082	I	See footnote (4) See footnote		
stock							79,082	1	<u>(5)</u>	·	
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.											
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)											
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactio Code (Instr. 8)	onDeriv Secur Acqu	rities ired (A) sposed of : 3, 4,	Expiration D	Expiration Date U		7. Title and Amount of Underlying Securities (Instr. 3 and 4)	
				Code V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	
Stock option (right to buy)	\$ 0.3025	05/30/2018		M <u>(1)</u>		5,962	<u>(6)</u>	08/12/2019	Common stock	5,962	
Stock option (right to buy)	\$ 0.3025	05/30/2018		M <u>(1)</u>		16,193	(7)	08/12/2019	Common stock	16,193	
Stock option (right to buy)	\$ 0.4675	05/30/2018		M <u>(1)</u>		23,471	(8)	03/01/2021	Common stock	23,471	

Reporting Owners

Reporting Owner Name / Address	Relationships						
	Director	10% Owner	Officer	Other			
Schenkein David P	Х		Chief Executive Officer				
C/O AGIOS PHARMACEUTICALS, INC.							
88 SIDNEY STREET							

8 I S (

CAMBRIDGE, MA 02139

Signatures

/s/ William Cook, as Attorney in Fact for David Schenkein

06/01/2018

**Signature of Reporting Person

Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
- (2) This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of \$90.00 to \$90.63. The (3) reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

- (4) Shares held by David P. Schenkein 2004 Revocable Trust, of which the reporting person is trustee and beneficiary.
- (5) Shares held by Amy P. Schenkein 2004 Revocable Trust, of which the reporting person's spouse is trustee and beneficiary.
- (6) This option was granted on August 13, 2009. The shares underlying this option vested as to 25% of the shares on August 1, 2010, and the remaining 75% vested in 36 equal monthly installments thereafter.

This option was granted on August 13, 2009. The shares underlying this option vested as to 50% upon the achievement of a performance
(7) milestone, as determined by the issuer's Board of Directors on June 3, 2010, and the remaining 50% of the underlying shares vested in equal monthly installments through June 3, 2013.

This option was granted on March 2, 2011. The shares underlying this option vested as to 25% of the shares on the date of grant and as to 25% of the shares upon the achievement of a performance milestone on July 19, 2013. The remaining 50% of the shares underlying the option vested in equal monthly installments through July 19, 2015.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.